SCHEMBL1742541

SCHEMBL1742541

CC(=O)Nc1ccc(-c2ccc(Cl)nn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.56
HTT P42858 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KMT2A Q03164 6/20 0.55
KDM4E B2RXH2 5/20 0.55
MEN1 O00255 5/20 0.55
ALDH1A1 P00352 5/20 0.55
MAPT P10636 4/20 0.55
HPGD P15428 4/20 0.55
RXFP1 Q9HBX9 2/20 0.55
POLB P06746 3/20 0.52
LMNA P02545 2/20 0.52
GAA P10253 2/20 0.51
PRNP P04156 1/20 0.51
NPSR1 Q6W5P4 1/20 0.50
CYP2C19 P33261 1/20 0.50
OGT O15294 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10389628 0.82 BRAF (0.55) SMN1; SMN2KDM4EALDH1A1MAPTRXFP1
SCHEMBL20937492 0.81 SMN1; SMN2 (0.56) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL15533892 0.78 KDM4E (0.56) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL1743284 0.77 KDM4E (0.55) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL4407327 0.76 SMN1; SMN2 (0.55) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL13588460 0.75 KMT2A (0.65) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL939046 0.74 KIF11 (0.57) SMN1; SMN2HTTKMT2AKDM4EMEN1
SCHEMBL3818831 0.74 SMN1; SMN2 (1.00) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL1743187 0.74 SMN1; SMN2 (0.51) SMN1; SMN2HTTL3MBTL1KMT2AKDM4E
SCHEMBL14384589 0.73 SMN1; SMN2 (0.79) SMN1; SMN2HTTL3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
CN-101218206-A Histamine H3 receptor antagonists NOVO NORDISK AS (DK) 2008-07-09 CN disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 SMN1; SMN2 3870/4885HTT 1487/4885L3MBTL1 4157/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 SMN1; SMN2 3870/4885HTT 1487/4885L3MBTL1 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.